CARSGEN-B (02171) Surges Over 4% as Kailimei® Research Findings Presented as Poster at ESMO Annual Meeting

Stock News11-04

Shares of CARSGEN-B (02171) rose more than 4%, reaching HK$10.9 as of press time, up 4.21%, with a turnover of HK$14.0204 million.

On the news front, CARSGEN-B recently announced that the preliminary results of a clinical trial (CT041-CG4010, NCT06857786) conducted in China for Kailimei® (satricabtagene autoleucel injection, product code: CT041, a Claudin18.2-targeting autologous CAR-T cell therapy candidate) as consolidation treatment following adjuvant therapy for patients with Claudin18.2-positive gastric/gastroesophageal junction cancer after radical resection were presented as a poster at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting on Sunday, October 25, 2026, from 12:00 to 12:45 Central European Summer Time (CEST).

Previously, on June 22, 2026, CARSGEN-B received notification from the National Medical Products Administration (NMPA) approving the new drug application for its independently developed Claudin18.2 autologous humanized CAR-T cell therapy product — Kailimei® (satricabtagene autoleucel injection) — for the treatment of Claudin18.2-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced gastric/gastroesophageal junction adenocarcinoma that has failed at least second-line treatment.

It is reported that Kailimei® is the world's first approved CAR-T cell therapy product for the treatment of solid tumors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment